Marion Subklewe

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele et al. · Blood · 2021 · 718 citations · Full text

Medicine, Hematology, Oncology +17

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Nora Philipp, Maryam Kazerani, Alyssa Nicholls et al. · Blood · 2022 · 245 citations · Full text

Life Sciences, Immunology, Oncology +17

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Wolfgang Bethge, Peter Martus, Michael Schmitt et al. · Blood · 2022 · 211 citations · Full text

Medicine, Hematology, Oncology +15

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management

Kai Rejeski, Michael D. Jain, Nirali N. Shah et al. · The Lancet Haematology · 2024 · 96 citations · Full text

Medicine, Hematology, Immunology +17

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, Anthony S. Stein, Roland B. Walter et al. · Blood · 2019 · 90 citations

Medicine, Hematology, Oncology +17